Novonesis Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Novonesis's earnings have been declining at an average annual rate of -1.3%, while the Chemicals industry saw earnings growing at 7.9% annually. Revenues have been growing at an average rate of 8.1% per year. Novonesis's return on equity is 2.6%, and it has net margins of 9.3%.

Anahtar bilgiler

-1.3%

Kazanç büyüme oranı

-0.6%

EPS büyüme oranı

Chemicals Sektör Büyümesi13.1%
Gelir büyüme oranı8.1%
Özkaynak getirisi2.6%
Net Marj9.3%
Sonraki Kazanç Güncellemesi07 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05
An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Jul 09
Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Jun 24
Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

May 02
Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Apr 07
Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 26
Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Mar 12
Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Feb 04
Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jan 29
Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Dec 23
Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Dec 05
Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Oct 14
A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13
These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29
The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13
Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13
Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29
Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12
Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Gelir ve Gider Dağılımı

Novonesis nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

CPSE:NSIS B Gelir, gider ve kazançlar (EUR Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 243,045283575326
31 Mar 242,696332506298
31 Dec 232,401406446271
30 Sep 232,390430441270
30 Jun 232,382460446272
31 Mar 232,390487441270
31 Dec 222,360494430267
30 Sep 222,268460443262
30 Jun 222,186418418257
31 Mar 222,090416403257
31 Dec 212,009423380266
30 Sep 211,958427335268
30 Jun 211,914409322274
31 Mar 211,883389310270
31 Dec 201,883380309256
30 Sep 201,920415309248
30 Jun 201,955405326254
31 Mar 201,968439335264
31 Dec 191,924422329263
30 Sep 191,923411334262
30 Jun 191,917434321260
31 Mar 191,922417315249
31 Dec 181,927432313248
30 Sep 181,924427311254
30 Jun 181,915429310247
31 Mar 181,920423320248
31 Dec 171,952419332255
30 Sep 171,958421334255
30 Jun 171,934412332254
31 Mar 171,919414328251
31 Dec 161,902410325251
30 Sep 161,864394327247
30 Jun 161,883394333253
31 Mar 161,883384331259
31 Dec 151,876378330254
30 Sep 151,840366320255
30 Jun 151,795353314252
31 Mar 151,741340311243
31 Dec 141,673339306237
30 Sep 141,641334314227
30 Jun 141,605324310216
31 Mar 141,598319312211
31 Dec 131,575295311205

Kaliteli Kazançlar: NSIS B has a large one-off loss of €105.1M impacting its last 12 months of financial results to 30th June, 2024.

Büyüyen Kar Marjı: NSIS B's current net profit margins (9.3%) are lower than last year (19.3%).


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: NSIS B's earnings have declined by 1.3% per year over the past 5 years.

Büyüme Hızlandırma: NSIS B's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Kazançlar vs. Sektör: NSIS B had negative earnings growth (-38.5%) over the past year, making it difficult to compare to the Chemicals industry average (-6.3%).


Özkaynak Getirisi

Yüksek ROE: NSIS B's Return on Equity (2.6%) is considered low.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin